Brittaney Howell
Family · Lake City, FLNPI 1316661929
Payments from drug & device makers
Across 125 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$599
- Amgen$227
- Lilly USA, LLC$187
- Merck$125
- GSK$93
- Novartis$88
- plus $759 from 21 others
What the payments were for
- Food & beverage$2,077100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $599 |
| Amgen | 13 | $227 |
| Lilly USA, LLC | 11 | $187 |
| Merck | 6 | $125 |
| GSK | 6 | $93 |
| Novartis | 4 | $88 |
| Pfizer | 4 | $79 |
| AbbVie | 3 | $74 |
| Edwards Lifesciences | 2 | $73 |
| Exact Sciences | 4 | $64 |
| AstraZeneca | 3 | $45 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Mylan Specialty L.p. | 2 | $36 |
| Bayer | 2 | $36 |
| Corcept Therapeutics | 2 | $31 |
| Vifor Pharma, Inc. | 1 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Boston Scientific | 1 | $28 |
| BD | 1 | $27 |
| Lundbeck LLC | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
How this compares
$2,077 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $27,422 |
| FarxigaDapagliflozin Propanediol | 16 | $24,245 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $23,823 |
| OzempicSemaglutide | 17 | $21,938 |
| EntrestoSacubitril/Valsartan | 19 | $21,135 |
| JardianceEmpagliflozin | 16 | $15,006 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $10,509 |
| JanuviaSitagliptin Phosphate | 11 | $6,089 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $6,042 |
| Losartan Potassium | 132 | $1,341 |
| Atorvastatin Calcium | 143 | $980 |
| Rosuvastatin Calcium | 78 | $950 |
| Ezetimibe | 65 | $865 |
| Levothyroxine Sodium | 81 | $804 |
| Gabapentin | 26 | $674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $79 | $27,42225 claims |
| AstraZenecaFarxiga | $45 | $24,24516 claims |
| GSKTrelegy Ellipta | $93 | $23,82323 claims |
| Novo NordiskOzempic | $599 | $21,93817 claims |
| NovartisEntresto | $88 | $21,13519 claims |
| MerckJanuvia | $125 | $6,08911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.
Other family in Lake City
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.